Introduction: Despite evidence that quitting smoking improves cancer treatment and outcomes, about one in eight patients with cancer smokes cigarettes. The standard of care tobacco treatment, behavioral counseling and medication, may not effectively address their psychosocial barriers to quitting, such as psychological distress and emotion dysregulation related to cancer diagnosis and treatment. This qualitative study evaluated our novel intervention to improve cessation self-efficacy by teaching patients skills in emotion regulation, distress tolerance, and mindfulness. We adapted our virtual, eight-session group intervention from Dialectical Behavior Therapy Skills Training (DBT ST). As a brief intervention, DBT ST has been successfully applied to treat similar conditions, enhancing coping skills and improving outcomes for patients with substance use disorders and patients with breast cancer. DBT ST has not yet been applied to address smoking cessation in cancer populations. Methods: We conducted qualitative interviews with eight patient participants with cancer who smoked or had quit and nine provider participants: oncologists, psychotherapists, and nurses. Interviews were analyzed using thematic analysis. Results: Patients and providers strongly supported the intervention, notably the group format and DBT ST skills for being more present, managing emotions, and handling stress, while sharing mixed opinions on other components, such as its virtual setting and time commitment. Other perceived benefits were improved quality of life, enhanced social support, decreased anxiety and depression, and acquisition of universal skills for managing life challenges. Conclusions: These qualitative results indicate early enthusiasm and promise for our DBT ST brief intervention, suggesting its potential for further development for patients with cancer who smoke cigarettes.

The authors have declared no competing interest.

This study was funded in part by the Qualitative and Patient-Reported Outcomes Shared Resource of the Wake Forest Baptist Comprehensive Cancer Center NCI Cancer Center Support Grant P30CA012197.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Institutional Review Board of the Wake Forest University School of Medicine gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors